<DOC>
	<DOCNO>NCT02847767</DOCNO>
	<brief_summary>The high dose per fraction ( &gt; 10Gy/fraction ) use Stereotactic Ablative Body Radiotherapy ( SABR ) show effective local tumor control treatment employ conventional dose fraction . The mechanism currently debate . One possible mechanism increase effectiveness high dose/fraction cause significant vascular damage tumor . This study hop measure vascular integrity pre post SABR treatment use kinetic model obtain dynamic contrast enhance CT .</brief_summary>
	<brief_title>Dynamic Contrast Enhanced HCC SABR Liver Study</brief_title>
	<detailed_description>Purpose : The purpose study determine high dose per fraction SABR impact vasculature tumor healthy liver tissue . Hypothesis : High dose / fraction HCC patient tumours &lt; 5 cm result detectable change kinetic model parameter derive dynamic contrast enhance image . Objectives : Primary objective : To quantify change tumor vascular support patient receive SABR . Secondary objective : To investigate correlation PK derive model liver perfusion parameter QoL metric measure EORTC QLQ-C30 FACT-Hep QoL assessment . Research Methods : Target population patient receive liver SABR 2 discrete liver tumor maximum dimension &lt; 5cm . Perfusion CT Image Data Post Processing Analysis . Patient motion correct use deformable registration , fiducial tracking , RPM breathe trace . Organ ROIs add perfusion image series manually translate anatomical planning CT ROIs motion-corrected perfusion image series , algorithmically deform plan ROIs . Portal vein abdominal aorta ROIs demarcate . Analysis proceed via custom software build related project . Contrast enhancement time course generate key structure ( i.e. , abdominal aorta , portal vein , gross liver tissue ) use derive variety perfusion map image , liver perfusion , mean transit time , arterial fraction , distribution volume . A distributed parameter model prefer kinetic modeling . Supplementary non-parametric technique use parameter interest ( e.g. , IAUC , maximum slope ) . Images acquire treatment register parameter map compare per-patient basis . Changes perfusion parameter characterize special emphasis place regional structure cluster effect . Pre post parameter map compute near individual-voxel level . Regions interest ( 1 ) within near tumour ( 2 ) low-dose portion liver define . A distribution parameter within ROI use generate estimate mean parameter uncertainty . Estimates mean parameter whole distribution compare use standard statistical comparison ( t-test Whitney respectively ) . Quality Life We evaluate quality life ( QOL ) HCC patient treat SBRT use EORTC QLQ-C30 FACT-Hep QOL assessment baseline , 3 , 6 , 9 12 month . Correlation perfusion parameter change patient outcome QOL ( second-order analysis ) apply statistically significant first-order parameter change detect . Standard correlative measure Pearson product-moment correlation measure use assess statistical significance . As currently data relate liver perfusion toxicity quality life , study examine whether change liver perfusion correlate enhance reduced QOL .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>All following criterion must meet : 1 . Age &gt; 18 year old 2 . Multiphase CT scan and/or MRI liver within 8 week radiation plan demonstrating : Liver tumours &lt; 5 cm No 2 discrete liver tumours Normal liver &gt; 700 cc 3 . Patients must HCC diagnose either : ) pathological confirmation , ii ) intrahepatic vascular enhancement lesion demonstrate least two image modality , iii ) intrahepatic vascular enhancement lesion demonstrate one imaging modality AFP &gt; 200 set liver cirrhosis chronic hepatitis B without cirrhosis ( EASL consensus guideline [ 2 ] ) 4 . Liver HCC must deem unresectable determine experienced hepatobiliary surgeon , patient must medically inoperable refuse surgery , 5 . Patients must discuss multidisciplinary setting , representative Medical Oncology , Radiation Oncology , Surgery , Interventional Radiology , Hepatology . Patients must consider ineligible standard local treatment , include surgery , liver transplantation , radiofrequency ablation , target biologics . Some subject could potential candidate sorafenib normally treatment consider local treatment option consider , response rate sorafenib low ( 2 % SHARP study ) . Patients might candidate sorafenib progression study treatment want participate case refer medical oncologist . Patients may receive prior TACE incomplete response . Ineffective incomplete TACE define incomplete fill lipiodoldoxorubicin mixture use either angiography CT ≥1 month TACE increase alphafetoprotein level . Patients must recover effect previous therapy SBRT minimum 4week period TACE SBRT . 6 . Eastern Clinical Oncology Group performance status 0 , 1 , 2 ( Appendix III ) , Karnofsky performance status ≥ 60 ( Appendix IV ) 7 . Adequate organ function assess follow blood work : Hemoglobin ≥ 90 g/L Absolute neutrophil count ≥ 1.0 bil/L Platelets ≥ 50 bil/L AST ALT exceed 3x upper limit normal 8 . ChildTurcottePugh assessment within 8 week treatment date ( Appendix II ) : Bilirubin ≤ 3 mg/dL ( &lt; 50 µmol/L ) Albumin 28 g/L INR &lt; 1.7 and/or correctable vitamin K ( unless anticoagulation therapy ) No ascites encephalopathy ChildTurcottePugh score must ≤ 7 9 . BCLC Stage B C ( portal venous invasion liver hilum nodal disease ; ( Appendix I ) 10 . Life expectancy &gt; 6 month 11 . No chemotherapy systemic therapy concurrent radiotherapy 12 . Previous treatment ( ) radiofrequency ablation , surgery , TACE , Y90 , percutaneous ethanol injection , chemotherapy exclusion criterion provide recurrence lack tumour response document . Patients decline , eligible , treatment also consider eligible . 13 . Patient sign studyspecific inform consent form . If patient 's mental status precludes , write informed consent may give patient 's legal representative . A translator provide patient language barrier . 14 . Treatment plan meet acceptable dose constraint Liver Veff ≤ 0.55 1 . Patients active hepatitis , encephalopathy , ascites relate liver failure 2 . Female patient pregnant ( verify blood test patient premenopausal ) . Premenopausal patient may also become pregnant participation study . 3 . Prior external beam radiation upper abdomen 4 . Patients distant metastasis extrahepatic nodal progression ( patient portal venous thrombosis liver hilum nodal involvement remain eligible ) 5 . Patients &lt; 700 cc normal liver . 6 . ChildTurcottePugh score &gt; 7 7 . BCLC Stage A , C ( N1 and/or M1 ) , D 8 . Prior gastric , duodenal , variceal bleed within past 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Liver Perfusion</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Dynamic Contrast-Enhanced Computed Tomography</keyword>
</DOC>